| scholarly article | Q13442814 |
| editorial | Q871232 |
| P356 | DOI | 10.1016/S0168-8278(98)80133-5 |
| P698 | PubMed publication ID | 9875652 |
| P2093 | author name string | Wedemeyer H | |
| Manns MP | |||
| Caselmann WH | |||
| P2860 | cites work | Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide | Q28240029 |
| A pilot study of ribavirin therapy for chronic hepatitis C | Q28318414 | ||
| Ribavirin antagonizes the effect of azidothymidine on HIV replication | Q28337829 | ||
| Inhibition of immune functions by antiviral drugs | Q34264407 | ||
| Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. | Q36865888 | ||
| Molecular mechanisms of action of ribavirin | Q38016839 | ||
| Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C. | Q38349527 | ||
| Effect of ribavirin on viral hepatitis in laboratory animals | Q40181634 | ||
| Hepatitis B virus immunopathogenesis | Q40444875 | ||
| Type 2 cytokines and negative immune regulation in human infections | Q40769749 | ||
| The treatment of chronic viral hepatitis | Q41332870 | ||
| Th1-Th2: reliable paradigm or dangerous dogma? | Q41574419 | ||
| Therapy of hepatitis C: overview | Q41598802 | ||
| Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation | Q42546923 | ||
| Prolonged therapy of chronic hepatitis C with ribavirin | Q42552575 | ||
| Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study | Q42631724 | ||
| Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study | Q42980410 | ||
| Long-term outcome of hepatitis C virus infection after liver transplantation | Q42980794 | ||
| Graft loss following liver transplantation in patients with chronic hepatitis C. | Q42980867 | ||
| Histological and clinical outcome after liver transplantation for hepatitis C. | Q42985828 | ||
| Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group | Q42986315 | ||
| Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial | Q43034904 | ||
| A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. | Q43036080 | ||
| Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone | Q43037990 | ||
| Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients | Q43039751 | ||
| Interferon-alpha therapy for hepatitis C virus infection after liver transplantation | Q43041374 | ||
| Long-term outcome of hepatitis C infection after liver transplantation | Q43046814 | ||
| Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon | Q43049218 | ||
| T-lymphocyte response to hepatitis C virus in different clinical courses of infection | Q44044022 | ||
| Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report | Q44710068 | ||
| Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo | Q45759262 | ||
| Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. | Q50588393 | ||
| Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. | Q50588396 | ||
| Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. | Q50588451 | ||
| Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. | Q50588728 | ||
| Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. | Q50589317 | ||
| Ribavirin treatment for chronic hepatitis C | Q50590272 | ||
| P433 | issue | 6 | |
| P921 | main subject | chronic hepatitis C | Q55779873 |
| P304 | page(s) | 1010-1014 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Combination therapy of chronic hepatitis C: an important step but not the final goal! | |
| P478 | volume | 29 |
| Q28344042 | Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon |
| Q41969753 | Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C virus gene expression in vitro and in vivo |
| Q43042207 | Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus |
| Q40687696 | Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus |
| Q50586981 | Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. |
| Q46770513 | Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin |
| Q34631375 | Management of viral hepatitis C. |
| Q35669529 | Mechanisms of hepatitis C virus infection |
| Q43041133 | Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. |
Search more.